Pipeline

We are harnessing the dynamic rules of amyloid assembly to design novel small-molecule medicines that block the generation of toxic fleeting protein intermediates that are central to neurodegenerative disease pathways, focusing first on Alzheimer's disease and Parkinson’s disease.

Pipeline